Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. (301096) — Cash Flow Reinvestment Rate
Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. (301096) has a Cash Flow Reinvestment Rate of 16.10x as of December 2023, reinvesting CN¥1.46 Billion (capex CN¥688.60 Million plus investments CN¥-767.42 Million) from operating cash flow of CN¥90.45 Million. Check 301096 operating cash flow to net income to evaluate the quality of earnings relative to operating cash generation.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. Cash Flow Reinvestment Rate (2019–2023)
Historical reinvestment intensity for Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. across 5 annual periods. Explore Hangzhou Bio-Sincerity Pharma-Tech Co.Lt cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.
Annual Cash Flow Reinvestment Rate for Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. (2019–2023)
Year-by-year capital reinvestment analysis for Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd.. For live market cap and broader valuation context, see 301096 market cap.
| Year | Reinvestment Rate | Total Reinvested (CNY) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2023 | 16.10x | CN¥1.46 Billion | CN¥90.45 Million | CN¥688.60 Million | ▲ +225.6% |
| 2022 | 4.94x | CN¥1.28 Billion | CN¥259.41 Million | CN¥591.58 Million | ▲ +43.9% |
| 2021 | 3.44x | CN¥499.61 Million | CN¥145.42 Million | CN¥248.45 Million | ▼ -63.4% |
| 2020 | 9.40x | CN¥510.91 Million | CN¥54.36 Million | CN¥255.12 Million | ▲ +217.8% |
| 2019 | 2.96x | CN¥211.38 Million | CN¥71.47 Million | CN¥106.95 Million | — |